<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39370676</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1601-0825</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Oct</Month><Day>06</Day></PubDate></JournalIssue><Title>Oral diseases</Title><ISOAbbreviation>Oral Dis</ISOAbbreviation></Journal><ArticleTitle>Oropharyngeal Adverse Events to Drugs and Vaccines: Pharmacovigilance Data From Italy (2019-2021).</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1111/odi.15145</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">The aim of this study was to perform a descriptive analysis of oropharyngeal adverse events (AEs) related to drugs and/or vaccines in order to provide useful information for clinicians.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Data related to three regions of Italy were analyzed from 2019 to 2021 by using the National Pharmacovigilance database.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Among overall 67,384 cases, 2773 (4.1%) reported at least one oropharyngeal AE. Most cases referred to females (71.0%) and adults (70.8%). The majority of cases were reported as not serious (68.4%) and the outcome was mainly positive (73.5%). The cases related to drugs (52.2%) were slightly more than those related to vaccines (47.8%), the latter nearly completely represented by COVID-19 vaccines. Among 3324 oropharyngeal AEs, the most commonly reported were oropharyngeal conditions (65.9%). The most reported AEs related to vaccines were paresthesia oral and oropharyngeal pain, whereas the most reported AEs related to drugs were throat tightness and angioedema. A marked under-reporting of osteonecrosis of the jaw (2.9%) was observed, despite this risk was well documented in the same country.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This analysis suggested an under-reporting of oropharyngeal AEs and the need to better train dentists, dental hygienists, and also general practitioners.</AbstractText><CopyrightInformation>© 2024 The Author(s). Oral Diseases published by John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Liberata</LastName><ForeName>Sportiello</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-5884-9889</Identifier><AffiliationInfo><Affiliation>Campania Regional Centre for Pharmacovigilance and Pharmacoepidemiology, University of Campania "Luigi Vanvitelli", Naples, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Experimental Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gaetano</LastName><ForeName>La Mantia</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Unit of Oral Medicine and Dentistry for Fragile Patients, Department of Rehabilitation, Fragility, and Continuity of Care, University Hospital Palermo, Palermo, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department Me.Pre.CC, University of Palermo, Palermo, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, Messina, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vera</LastName><ForeName>Panzarella</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0001-6339-6020</Identifier><AffiliationInfo><Affiliation>Department Me.Pre.CC, University of Palermo, Palermo, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Giuseppe</LastName><ForeName>Colella</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Oral and Maxillofacial Surgery Unit, Multidisciplinary Department of Medical-Surgical and Dental Specialties, University of Campania "Luigi Vanvitelli", Naples, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Simona</LastName><ForeName>Potenza</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Italian Medicines Agency, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Giacomo</LastName><ForeName>Oteri</ForeName><Initials>O</Initials><Identifier Source="ORCID">0000-0002-0941-1645</Identifier><AffiliationInfo><Affiliation>Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, Messina, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Laura</LastName><ForeName>Sottosanti</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Italian Medicines Agency, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Giuseppe</LastName><ForeName>Bellavia</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Drug, ASP Agrigento, Agrigento, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mario</LastName><ForeName>Gaio</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0003-4287-5510</Identifier><AffiliationInfo><Affiliation>Campania Regional Centre for Pharmacovigilance and Pharmacoepidemiology, University of Campania "Luigi Vanvitelli", Naples, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Experimental Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alessia</LastName><ForeName>Zinzi</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Campania Regional Centre for Pharmacovigilance and Pharmacoepidemiology, University of Campania "Luigi Vanvitelli", Naples, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Experimental Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ilaria</LastName><ForeName>Morreale</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Internal Medicine, Pharmacovigilance and Clinical Pharmacology Unit, Department of Promoting Health, Maternal-Infant, Excellence and Internal and Specialized Medicine (PROMISE) G. D'Alessandro, Sicilian Regional Pharmacovigilance Centre, University of Palermo, Palermo, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gaspare</LastName><ForeName>Parrinello</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Promoting Health, Maternal-Infant, Excellence and Internal and Specialized Medicine (PROMISE) G. D'Alessandro, University of Palermo, Palermo, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Elisabetta</LastName><ForeName>Geninatti</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Piedmont Regional Centre for Pharmacovigilance, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eleonora</LastName><ForeName>Marrazzo</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Piedmont Regional Centre for Pharmacovigilance, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vittorio</LastName><ForeName>Fusco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Oncology Unit, Azienda Ospedaliera Di Alessandria SS. Antonio e Biagio e Cesare Arrigo, Alessandria, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Annalisa</LastName><ForeName>Capuano</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Campania Regional Centre for Pharmacovigilance and Pharmacoepidemiology, University of Campania "Luigi Vanvitelli", Naples, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Experimental Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Giuseppina</LastName><ForeName>Campisi</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-9443-0495</Identifier><AffiliationInfo><Affiliation>Unit of Oral Medicine and Dentistry for Fragile Patients, Department of Rehabilitation, Fragility, and Continuity of Care, University Hospital Palermo, Palermo, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedicine, Neuroscience and Advanced Diagnostic, University of Palermo, Palermo, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>Denmark</Country><MedlineTA>Oral Dis</MedlineTA><NlmUniqueID>9508565</NlmUniqueID><ISSNLinking>1354-523X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">database</Keyword><Keyword MajorTopicYN="N">dentists</Keyword><Keyword MajorTopicYN="N">oropharyngeal adverse events</Keyword><Keyword MajorTopicYN="N">pharmacovigilance</Keyword><Keyword MajorTopicYN="N">spontaneous reporting</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>4</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>7</Day><Hour>10</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>7</Day><Hour>10</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>7</Day><Hour>1</Hour><Minute>53</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39370676</ArticleId><ArticleId IdType="doi">10.1111/odi.15145</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>Ahsanuddin, S., R. Jin, A. K. Dhanda, et al. 2023. “Otolaryngologic Side Effects After COVID‐19 Vaccination.” Laryngoscope 134, no. 3: 1163–1168. https://doi.org/10.1002/lary.30923.</Citation></Reference><Reference><Citation>Aronson, J. K. 2003. “Joining the DoTS: New Approach to Classifying Adverse Drug Reactions.” BMJ 327, no. 7425: 1222–1225. https://doi.org/10.1136/bmj.327.7425.1222.</Citation></Reference><Reference><Citation>Aswath, N., and R. Rakshana. 2022. “Drug Induced Erythema Multiforme of the Oral Cavity.” Archive of Clinical Cases 9, no. 4: 157–160. https://doi.org/10.22551/2022.37.0904.10224.</Citation></Reference><Reference><Citation>Bakhtiari, S., M. Sehatpour, H. Mortazavi, and M. Bakhshi. 2018. “Orofacial Manifestation of Adverse Drug Reactions: A Review Study.” Medicine and Pharmacy Reports 91, no. 1: 27–36. https://doi.org/10.15386/cjmed‐748.</Citation></Reference><Reference><Citation>Bedogni, A., S. Fedele, G. Bedogni, et al. 2014. “Staging of Osteonecrosis of the Jaw Requires Computed Tomography for Accurate Definition of the Extent of Bony Disease.” British Journal of Oral and Maxillofacial Surgery 52, no. 7: 603–608. https://doi.org/10.1016/j.bjoms.2014.04.009.</Citation></Reference><Reference><Citation>Bedogni, A., R. Mauceri, V. Fusco, et al. 2024. “Italian Position Paper (SIPMO‐SICMF) on Medication‐Related Osteonecrosis of the Jaw (MRONJ).” Oral Diseases 30, no. 6: 3679–3709. https://doi.org/10.1111/odi.14887.</Citation></Reference><Reference><Citation>Bharti, V., and C. Bansal. 2013. “Drug‐Induced Gingival Overgrowth: The Nemesis of Gingiva Unravelled.” Journal of Indian Society of Periodontology 17, no. 2: 182. https://doi.org/10.4103/0972‐124X.113066.</Citation></Reference><Reference><Citation>Binmadi, N. O., M. Bawazir, N. Alhindi, et al. 2020. “Medication‐Induced Oral Hyperpigmentation: A Systematic Review.” Patient Preference and Adherence 14: 1961–1968. https://doi.org/10.2147/PPA.S275783.</Citation></Reference><Reference><Citation>Blenkinsopp, A., P. Wilkie, M. Wang, and P. A. Routledge. 2007. “Patient Reporting of Suspected Adverse Drug Reactions: A Review of Published Literature and International Experience.” British Journal of Clinical Pharmacology 63, no. 2: 148–156. https://doi.org/10.1111/j.1365‐2125.2006.02746.x.</Citation></Reference><Reference><Citation>Brabete, A. C., L. Greaves, M. Maximos, E. Huber, A. Li, and M.‐L. Lê. 2022. “A Sex‐ and Gender‐Based Analysis of Adverse Drug Reactions: A Scoping Review of Pharmacovigilance Databases.” Pharmaceuticals 15, no. 3: 298. https://doi.org/10.3390/ph15030298.</Citation></Reference><Reference><Citation>Campisi, G., R. Mauceri, F. Bertoldo, et al. 2020. “Medication‐Related Osteonecrosis of Jaws (MRONJ) Prevention and Diagnosis: Italian Consensus Update 2020.” International Journal of Environmental Research and Public Health 17, no. 16: 5998. https://doi.org/10.3390/ijerph17165998.</Citation></Reference><Reference><Citation>Di Fede, O., V. Fusco, D. Matranga, et al. 2013. “Osteonecrosis of the Jaws in Patients Assuming Oral Bisphosphonates for Osteoporosis: A Retrospective Multi‐Hospital‐Based Study of 87 Italian Cases.” European Journal of Internal Medicine 24, no. 8: 784–790. https://doi.org/10.1016/j.ejim.2013.05.011.</Citation></Reference><Reference><Citation>D'Incau, P., M. Lapeyre‐Mestre, A. Carvajal, et al. 2014. “No Differences Between Men and Women in Adverse Drug Reactions Related to Psychotropic Drugs: A Survey From France, Italy and Spain.” Fundamental and Clinical Pharmacology 28, no. 3: 342–348. https://doi.org/10.1111/fcp.12032.</Citation></Reference><Reference><Citation>Ellefsen, B. S., K. R. Larsen, J. Reibel, and C. Kragelund. 2023. “Danish Post‐Marketing Pharmacosurveillance of Spontaneous Oral Adverse Drug Reactions 2009–2019.” Oral Diseases 30, no. 3: 1573–1582. https://doi.org/10.1111/odi.14559.</Citation></Reference><Reference><Citation>European Medicines Agency (EMA). 2023a. “Important Medical (IME) Event Terms List ‐ MedDRA Version 25.0 (2022).” https://www.ema.europa.eu/en/documents/other/meddra‐important‐medical‐event‐terms‐list‐version‐250_en.xlsx.</Citation></Reference><Reference><Citation>European Medicines Agency (EMA). 2009. “CHMP Assessment Report on Bisphosphonates and Osteonecrosis of the Jaw. EMEA/CHMP/291125/2009. Procedure Under Article 5(3) of Regulation (EC) No 726/2004.” https://www.ema.europa.eu/en/documents/report/chmp‐assessment‐report‐bisphosphonates‐osteonecrosis‐jaw‐procedure‐under‐article‐53‐regulation‐ec‐no/2004_en.pdf.</Citation></Reference><Reference><Citation>European Medicines Agency (EMA). 2013. “EMA/281412/2012. Patient Health Protection European Medicines Agency 2013 priorities for drug safety research.” Long term adverse skeletal effects of bisphosphonates. https://www.ema.europa.eu/en/documents/other/european‐medicines‐agency‐2013‐priorities‐drug‐safety‐research‐long‐term‐adverse‐skeletal‐effects_en.pdf.</Citation></Reference><Reference><Citation>European Medicines Agency (EMA). 2023b. “Pharmacovigilance: Overview.” https://www.ema.europa.eu/en/human‐regulatory/overview/pharmacovigilance‐overview.</Citation></Reference><Reference><Citation>Fadul, A., E. M. Abdalla, M. Musa, A. AL‐Mashdali, A. E. Mudathir Osman, and E. Abdelmahuod. 2022. “Sever Erythema Multiforme Post‐COVID‐19 Moderna Vaccine: Case Report and Literature Review.” Annals of Medicine and Surgery 83: 104461. https://doi.org/10.1016/j.amsu.2022.104461.</Citation></Reference><Reference><Citation>Ferlito, S., S. Puzzo, and C. Liardo. 2011. “Preventive Protocol for Tooth Extractions in Patients Treated With Zoledronate: A Case Series.” Journal of Oral and Maxillofacial Surgery 69, no. 6: e1–e4. https://doi.org/10.1016/j.joms.2010.10.055.</Citation></Reference><Reference><Citation>Figueiras, A., F. Tato, J. Fontaiñas, and J. J. Gestal‐Otero. 1999. “Influence of Physicians' Attitudes on Reporting Adverse Drug Events.” Medical Care 37, no. 8: 809–814. https://doi.org/10.1097/00005650‐199908000‐00010.</Citation></Reference><Reference><Citation>Franconi, F., S. Brunelleschi, L. Steardo, and V. Cuomo. 2007. “Gender Differences in Drug Responses.” Pharmacological Research 55, no. 2: 81–95. https://doi.org/10.1016/j.phrs.2006.11.001.</Citation></Reference><Reference><Citation>Fung, P., G. Bedogni, A. Bedogni, et al. 2017. “Time to Onset of Bisphosphonate‐Related Osteonecrosis of the Jaws: A Multicentre Retrospective Cohort Study.” Oral Diseases 23, no. 4: 477–483. https://doi.org/10.1111/odi.12632.</Citation></Reference><Reference><Citation>Fusco, V., M. Cabras, F. Erovigni, et al. 2021. “A Multicenter Observational Study on Medication‐Related Osteonecrosis of the Jaw (MRONJ) in Advanced Cancer and Myeloma Patients of a Cancer Network in North‐Western Italy.” Medicina Oral, Patología Oral y Cirugía Bucal 26: e466–e473. https://doi.org/10.4317/medoral.24318.</Citation></Reference><Reference><Citation>Fusco, V., C. Galassi, A. Berruti, et al. 2013. “Decreasing Frequency of Osteonecrosis of the Jaw in Cancer and Myeloma Patients Treated With Bisphosphonates: The Experience of the Oncology Network of Piedmont and Aosta Valley (North‐Western Italy).” ISRN Oncology 2013: 672027. https://doi.org/10.1155/2013/672027.</Citation></Reference><Reference><Citation>Fusco, V., R. Mauceri, G. Campisi, and A. Bedogni. 2022. “RE: American Association of Oral and Maxillofacial Surgeons' Position Paper on Medication‐Related Osteonecrosis of the Jaws—2022 Update: Quantitative Risk Assessment and Controversial Issues.” Journal of Oral and Maxillofacial Surgery 80, no. 12: 1871–1873. https://doi.org/10.1016/j.joms.2022.07.143.</Citation></Reference><Reference><Citation>Gell, P. G. H., and R. R. A. Coombs. 1963. “The Classification of Allergic Reactions Underlying Disease.” In Clinical Aspects of Immunology, edited by P. G. H. Gell and R. R. A. Coombs. Oxford: Blackwell Science.</Citation></Reference><Reference><Citation>Graziani, F., P. Vescovi, G. Campisi, et al. 2012. “Resective Surgical Approach Shows a High Performance in the Management of Advanced Cases of Bisphosphonate‐Related Osteonecrosis of the Jaws: A Retrospective Survey of 347 Cases.” Journal of Oral and Maxillofacial Surgery 70, no. 11: 2501–2507. https://doi.org/10.1016/j.joms.2012.05.019.</Citation></Reference><Reference><Citation>Gupta, R. 2003. “Drugs Causing Fixed Drug Eruptions: Confirmed by Provocation Tests.” Indian Journal of Dermatology, Venereology and Leprology 69, no. 2: 120–121.</Citation></Reference><Reference><Citation>Holm, L., E. Ekman, and K. Jorsäter Blomgren. 2017. “Influence of Age, Sex and Seriousness on Reporting of Adverse Drug Reactions in Sweden.” Pharmacoepidemiology and Drug Safety 26, no. 3: 335–343. https://doi.org/10.1002/pds.4155.</Citation></Reference><Reference><Citation>Italian Medicines Agency (AIFA). 2023. “Drug Safety. National Network of Pharmacovigilance.” AIFA Website. http://aifa.gov.it.</Citation></Reference><Reference><Citation>Italian National Institute of Statistics (Istat). 2023. “STATBASE: l'accesso ai Principali Dati.” http://dati.istat.it/viewhtml.aspx?il=blank&amp;vh=0000&amp;vf=0&amp;vcq=1100&amp;graph=0&amp;view‐metadata=1&amp;lang=it&amp;QueryId=18460&amp;metadata=DCIS_POPRES1.</Citation></Reference><Reference><Citation>Jose, J., A. R. Cox, and V. Paudyal (Eds.). 2024. Principles and Practice of Pharmacovigilance and Drug Safety. Springer International Publishing. https://doi.org/10.1007/978‐3‐031‐51089‐2.</Citation></Reference><Reference><Citation>La Mantia, G., F. Buttacavoli, V. Panzarella, et al. 2023. “Oro‐Dental Pharmacovigilance in the Digital Age: Promoting Knowledge, Awareness, and Practice in Italy Through a Smart Combined System—A Conference at the 30th National Congress of the Italian College of University Professors of Dental Disciplines.” Oral 3, no. 3: 411–419. https://doi.org/10.3390/oral3030033.</Citation></Reference><Reference><Citation>Li, R., K. Curtis, C. Van, et al. 2022. “Why Hospital‐Based Healthcare Professionals Do Not Report Adverse Drug Reactions: A Mixed Methods Study Using the Theoretical Domains Framework.” European Journal of Clinical Pharmacology 78, no. 7: 1165–1175. https://doi.org/10.1007/s00228‐022‐03326‐x.</Citation></Reference><Reference><Citation>Lo Russo, L., L. Guida, M. Di Masi, et al. 2012. “Adverse Drug Reactions in the Oral Cavity.” Current Pharmaceutical Design 18, no. 34: 5481–5496. https://doi.org/10.2174/138161212803307518.</Citation></Reference><Reference><Citation>Lopez‐Gonzalez, E., M. T. Herdeiro, and A. Figueiras. 2009. “Determinants of Under‐Reporting of Adverse Drug Reactions.” Drug Safety 32, no. 1: 19–31. https://doi.org/10.2165/00002018‐200932010‐00002.</Citation></Reference><Reference><Citation>Lu, S.‐Y. 2021. “Oral Candidosis: Pathophysiology and Best Practice for Diagnosis, Classification, and Successful Management.” Journal of Fungi 7, no. 7: 555. https://doi.org/10.3390/jof7070555.</Citation></Reference><Reference><Citation>Lugović‐Mihić, L. 2018. “Differential Diagnosis of Cheilitis – How to Classify Cheilitis?” Acta Clinica Croatica 57, no. 2: 342–351. https://doi.org/10.20471/acc.2018.57.02.16.</Citation></Reference><Reference><Citation>Mascolo, A., R. Di Napoli, N. Balzano, et al. 2023. “Which Is the Top Player for the Cardiovascular Safety? Ibrutinib vs. Obinutuzumab in CLL.” Frontiers in Pharmacology 14: 1229304. https://doi.org/10.3389/fphar.2023.1229304.</Citation></Reference><Reference><Citation>MedDRA. 2023a. “MedDRA Maintenance and Service Organization.” Standardised MedDRA Queries. http://www.meddra.org/how‐to‐use/tools/smqs.</Citation></Reference><Reference><Citation>MedDRA SMQs. 2023. “MedDRA.” Introductory Guide for Standardised MedDRA Queries (SMQs) Version 26.0 March 2023 000912. https://admin.meddra.org/sites/default/files/guidance/file/SMQ_intguide_26_0_English.pdf.</Citation></Reference><Reference><Citation>Medical Dictionary for Regulatory Activities (MedDRA). 2023b. “Medical Dictionary for Regulatory Activities (MedDRA).” MedDRA Website. https://www.meddra.org.</Citation></Reference><Reference><Citation>Montes‐Grajales, D., R. Garcia‐Serna, and J. Mestres. 2023. “Impact of the COVID‐19 Pandemic on the Spontaneous Reporting and Signal Detection of Adverse Drug Events.” Scientific Reports 13, no. 1: 18817. https://doi.org/10.1038/s41598‐023‐46275‐w.</Citation></Reference><Reference><Citation>Oteri, G., E. Bramanti, V. Nigrone, and M. Cicciù. 2013. “Decayed, Missing, and Filled Teeth Index and Periodontal Health in Osteoporotic Patients Affected by BRONJ: An Observational Study.” Journal of Osteoporosis 2013: 231289. https://doi.org/10.1155/2013/231289.</Citation></Reference><Reference><Citation>Oteri, G., G. Trifirò, M. Peditto, et al. 2018. “Treatment of Medication‐Related Osteonecrosis of the Jaw and Its Impact on a Patient's Quality of Life: A Single‐Center, 10‐Year Experience From Southern Italy.” Drug Safety 41, no. 1: 111–123. https://doi.org/10.1007/s40264‐017‐0582‐6.</Citation></Reference><Reference><Citation>Otto, S., M. H. Abu‐Id, S. Fedele, et al. 2011. “Osteoporosis and Bisphosphonates‐Related Osteonecrosis of the Jaw: Not Just a Sporadic Coincidence – A Multi‐Centre Study.” Journal of Cranio‐Maxillofacial Surgery 39, no. 4: 272–277. https://doi.org/10.1016/j.jcms.2010.05.009.</Citation></Reference><Reference><Citation>Ouanounou, A., K. Ng, and P. Chaban. 2020. “Adverse Drug Reactions in Dentistry.” International Dental Journal 70, no. 2: 79–84. https://doi.org/10.1111/idj.12540.</Citation></Reference><Reference><Citation>Parés‐Badell, O., X. Martínez‐Gómez, L. Pinós, et al. 2021. “Local and Systemic Adverse Reactions to mRNA COVID‐19 Vaccines Comparing Two Vaccine Types and Occurrence of Previous COVID‐19 Infection.” Vaccine 9, no. 12: 1463. https://doi.org/10.3390/vaccines9121463.</Citation></Reference><Reference><Citation>Parretta, E., C. Rafaniello, L. Magro, et al. 2014. “Improvement of Patient Adverse Drug Reaction Reporting Through a Community Pharmacist‐Based Intervention in the Campania Region of Italy.” Expert Opinion on Drug Safety 13, no. sup1: 21–29. https://doi.org/10.1517/14740338.2014.939582.</Citation></Reference><Reference><Citation>Parretta, E., L. Sottosanti, L. Sportiello, et al. 2014. “Bisphosphonate‐Related Osteonecrosis of the Jaw: An Italian Post‐Marketing Surveillance Analysis.” Expert Opinion on Drug Safety 13, no. sup1: 31–40. https://doi.org/10.1517/14740338.2014.951329.</Citation></Reference><Reference><Citation>Potlog Shchory, M., L. H. Goldstein, L. Arcavi, R. Shihmanter, M. Berkovitch, and A. Levy. 2020. “Increasing Adverse Drug Reaction Reporting—How Can We Do Better?” PLoS One 15, no. 8: e0235591. https://doi.org/10.1371/journal.pone.0235591.</Citation></Reference><Reference><Citation>Rademaker, M. 2001. “Do Women Have More Adverse Drug Reactions?” American Journal of Clinical Dermatology 2, no. 6: 349–351. https://doi.org/10.2165/00128071‐200102060‐00001.</Citation></Reference><Reference><Citation>Riad, A., A. Põld, E. Kateeb, and S. Attia. 2022. “Oral Adverse Events Following COVID‐19 Vaccination: Analysis of VAERS Reports.” Frontiers in Public Health 10: 952781. https://doi.org/10.3389/fpubh.2022.952781.</Citation></Reference><Reference><Citation>Riad, A., N. Schulz‐Weidner, A. Dziedzic, H. Howaldt, and S. Attia. 2023. “Oral Side Effects of COVID‐19 Vaccines in 32 European Countries: Analysis of EudraVigilance Reports.” Journal of Medical Virology 95, no. 5: e28771. https://doi.org/10.1002/jmv.28771.</Citation></Reference><Reference><Citation>Routray, R., N. Tetarenko, C. Abu‐Assal, et al. 2020. “Application of Augmented Intelligence for Pharmacovigilance Case Seriousness Determination.” Drug Safety 43, no. 1: 57–66. https://doi.org/10.1007/s40264‐019‐00869‐4.</Citation></Reference><Reference><Citation>Seselja Perisin, A., J. Bukic, D. Rusic, et al. 2021. “Teaching Pharmacovigilance to Healthcare Students: Identifying Gaps and Opportunities for Improvement.” Pharmacy 9, no. 3: 147. https://doi.org/10.3390/pharmacy9030147.</Citation></Reference><Reference><Citation>Suryana, K. 2020. “Lichenoid Reaction Caused by Antihistamines and Corticosteroids.” Journal of Asthma and Allergy 13: 205–211. https://doi.org/10.2147/JAA.S251046.</Citation></Reference><Reference><Citation>Teoh, L., G. Moses, and M. J. McCullough. 2019. “A Review and Guide to Drug‐Associated Oral Adverse Effects—Dental, Salivary and Neurosensory Reactions. Part 1.” Journal of Oral Pathology and Medicine 48, no. 7: 626–636. https://doi.org/10.1111/jop.12911.</Citation></Reference><Reference><Citation>Tofé, V. I., L. Bagán, and J. V. Bagán. 2020. “Osteonecrosis of the Jaws Associated With Denosumab: Study of Clinical and Radiographic Characteristics in a Series of Clinical Cases.” Journal of Clinical and Experimental Dentistry 12: e676–e681. https://doi.org/10.4317/jced.57019.</Citation></Reference><Reference><Citation>Tran, C., S. R. Knowles, B. A. Liu, and N. H. Shear. 1998. “Gender Differences in Adverse Drug Reactions.” Journal of Clinical Pharmacology 38, no. 11: 1003–1009. https://doi.org/10.1177/009127009803801103.</Citation></Reference><Reference><Citation>Vescovi, P., G. Campisi, V. Fusco, et al. 2011. “Surgery‐Triggered and Non Surgery‐Triggered Bisphosphonate‐Related Osteonecrosis of the Jaws (BRONJ): A Retrospective Analysis of 567 Cases in an Italian Multicenter Study.” Oral Oncology 47, no. 3: 191–194. https://doi.org/10.1016/j.oraloncology.2010.11.007.</Citation></Reference><Reference><Citation>Wan, J. T., D. M. Sheeley, M. J. Somerman, and J. S. Lee. 2020. “Mitigating Osteonecrosis of the Jaw (ONJ) Through Preventive Dental Care and Understanding of Risk Factors.” Bone Research 8, no. 1: 14. https://doi.org/10.1038/s41413‐020‐0088‐1.</Citation></Reference><Reference><Citation>Warner, B. M., A. N. Baer, E. J. Lipson, et al. 2019. “Sicca Syndrome Associated With Immune Checkpoint Inhibitor Therapy.” Oncologist 24, no. 9: 1259–1269. https://doi.org/10.1634/theoncologist.2018‐0823.</Citation></Reference><Reference><Citation>Watson, S., O. Caster, P. A. Rochon, and H. den Ruijter. 2019. “Reported Adverse Drug Reactions in Women and Men: Aggregated Evidence From Globally Collected Individual Case Reports During Half a Century.” EClinicalMedicine 17: 100188. https://doi.org/10.1016/j.eclinm.2019.10.001.</Citation></Reference><Reference><Citation>Yip, J., D. R. Radford, and D. Brown. 2013. “How Do UK Dentists Deal With Adverse Drug Reaction Reporting?” British Dental Journal 214, no. 8: E22. https://doi.org/10.1038/sj.bdj.2013.426.</Citation></Reference><Reference><Citation>Yousefian, M., and A. Khadivi. 2023. “Occurrence of Erythema Multiforme Following COVID‐19 Vaccination: A Review.” Clinical and Experimental Vaccine Research 12, no. 2: 87. https://doi.org/10.7774/cevr.2023.12.2.87.</Citation></Reference><Reference><Citation>Yuan, A., and S.‐B. Woo. 2015. “Adverse Drug Events in the Oral Cavity.” Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology 119, no. 1: 35–47. https://doi.org/10.1016/j.oooo.2014.09.009.</Citation></Reference><Reference><Citation>Yuan, A., and S.‐B. Woo. 2020. “Adverse Drug Events in the Oral Cavity.” Dermatologic Clinics 38, no. 4: 523–533. https://doi.org/10.1016/j.det.2020.05.012.</Citation></Reference><Reference><Citation>Zhang, X., M. Sumathipala, and M. Zitnik. 2021. “Population‐Scale Identification of Differential Adverse Events Before and During a Pandemic.” Nature Computational Science 1, no. 10: 666–677. https://doi.org/10.1038/s43588‐021‐00138‐4.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>